05 Oct 2026

Danish Regions (Danske Regioner) has transferred responsibility for assessing confidential prices in its outpatient medicines pilot to the Danish Medicines Council (Medicinrådet). The decision, announced on 2 October, separates clinical and economic assessment from price negotiations, which remain with Amgros.

The pilot began on 1 July 2025 and runs until June 2028. It allows confidential price agreements for selected medicines supplied through community pharmacies, including new treatments at risk of refusal of general reimbursement on price grounds and products undergoing reimbursement reassessment. Previously, a regionally appointed assessment group evaluated the negotiated terms before the regional directors decided whether they represented appropriate use of resources.

The Medicines Council now assesses whether treatment benefits justify costs at the negotiated price. The Danish Medicines Agency (Lægemiddelstyrelsen) retains responsibility for the formal decision on general or restricted reimbursement. The arrangement mirrors the established division between the Council and Amgros for hospital medicines.

The new assessment route applies to requests received from 1 October; earlier requests continue under the previous arrangements. The Council formally takes over the secretariat role on 1 November. Amgros had received 13 negotiation requests since the pilot began, more than initially expected.

Applicants will therefore engage with the Council on evaluation and with Amgros on commercial terms. The pilot's existing end date and statutory reimbursement decision-making remain unchanged.

Source: Danish Regions
Link: Medicinrådet overtager vurderinger af fortrolige priser på tilskudsmedicin (Medicines Council takes over assessment of confidential prices for reimbursed medicines)
Date: 2 October 2026